Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.

ABSTRACT:

Background & aims

Atezolizumab/bevacizumab (atezo/bev) has revolutionized the standard of care for patients with unresectable hepatocellular carcinoma (HCC). However, only a subgroup of patients responds to atezo/bev and derives durable clinical benefit. This study aims to analyze the frequency and risk factors of early mortality (EM) in patients with HCC treated with atezo/bev.

Methods

This study uses data from a large, European real-world cohort and flow cytometry-based immunophenotyping of patient's baseline PBMC. EM was defined as death from any cause within 90 days of treatment initiation. Logistic regression analysis was used to identify parameters associated with EM.

Results

A total of 317 patients with unresectable HCC treated with first-line atezo/bev were in

SUBMITTER: Piseddu I 

PROVIDER: S-EPMC12861967 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature